Valuation Metrics

Search documents
Amphenol Corporation (APH) Soars to 52-Week High, Time to Cash Out?
ZACKS· 2025-10-09 14:15
Have you been paying attention to shares of Amphenol (APH) ? Shares have been on the move with the stock up 5.6% over the past month. The stock hit a new 52-week high of $126.11 in the previous session. Amphenol has gained 81.1% since the start of the year compared to the 24.4% move for the Zacks Computer and Technology sector and the 80.6% return for the Zacks Electronics - Connectors industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten ...
UNIVERSAL INSURANCE HOLDINGS INC (UVE) Hit a 52 Week High, Can the Run Continue?
ZACKS· 2025-10-06 14:15
Have you been paying attention to shares of Universal Insurance Holdings (UVE) ? Shares have been on the move with the stock up 15.3% over the past month. The stock hit a new 52-week high of $28.61 in the previous session. Universal Insurance has gained 34.7% since the start of the year compared to the 14.4% gain for the Zacks Finance sector and the 9.5% return for the Zacks Insurance - Property and Casualty industry.What's Driving the Outperformance?The stock has a great record of positive earnings surpris ...
Aptiv PLC (APTV) Hits Fresh High: Is There Still Room to Run?
ZACKS· 2025-10-06 14:15
Have you been paying attention to shares of Aptiv PLC (APTV) ? Shares have been on the move with the stock up 9.4% over the past month. The stock hit a new 52-week high of $88.24 in the previous session. APTIV HLDS LTD has gained 45.5% since the start of the year compared to the 7.2% gain for the Zacks Auto-Tires-Trucks sector and the 17.6% return for the Zacks Automotive - Original Equipment industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it ...
Boyd Gaming Corporation (BYD) Hits Fresh High: Is There Still Room to Run?
ZACKS· 2025-10-03 14:16
Core Viewpoint - Boyd Gaming (BYD) has shown strong stock performance, reaching a new 52-week high and outperforming both the Zacks Consumer Discretionary sector and the Zacks Gaming industry in year-to-date returns [1][2]. Performance Metrics - Boyd's stock has increased by 20% since the beginning of the year, compared to a 9.1% increase in the Zacks Consumer Discretionary sector and a 24.8% return in the Zacks Gaming industry [1]. - The stock has consistently beaten earnings estimates, reporting an EPS of $1.87 against a consensus estimate of $1.67 in its last earnings report [2]. Earnings Projections - For the current fiscal year, Boyd is projected to achieve earnings of $6.91 per share with revenues of $3.77 billion, reflecting a 5.5% increase in EPS but a 4.04% decrease in revenues [3]. - The next fiscal year is expected to see earnings of $7.54 per share on revenues of $3.57 billion, indicating a year-over-year EPS growth of 9.12% but a revenue decline of 5.29% [3]. Valuation Metrics - Boyd's stock trades at 12.6 times the current fiscal year EPS estimates, significantly lower than the peer industry average of 25.6 times [7]. - The trailing cash flow multiple is 8.6 times, compared to the peer group's average of 11.9 times, and the PEG ratio stands at 2.45, positioning Boyd favorably for value investors [7]. Style Scores - Boyd has a Value Score of A, with Growth and Momentum Scores of C and B, respectively, resulting in a VGM Score of B [6]. - The Zacks Rank for Boyd is 2 (Buy), supported by a positive earnings estimate revision trend, making it a suitable choice for investors looking for stocks with strong potential [8].
NMR vs. HOOD: Which Stock Should Value Investors Buy Now?
ZACKS· 2025-10-01 16:41
Investors interested in Financial - Investment Bank stocks are likely familiar with Nomura Holdings (NMR) and Robinhood Markets, Inc. (HOOD) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trend ...
OSK vs. IR: Which Stock Should Value Investors Buy Now?
ZACKS· 2025-10-01 16:41
Investors interested in Manufacturing - General Industrial stocks are likely familiar with Oshkosh (OSK) and Ingersoll Rand (IR) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores ...
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue?
ZACKS· 2025-10-01 14:16
Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) has experienced significant stock performance, with a 23% increase over the past month and a 35.3% gain since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Biomedical and Genetics industry [1][3]. Financial Performance - The company has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters. In the latest earnings report on August 6, 2025, Arcutis reported an EPS of -$0.13, surpassing the consensus estimate of -$0.18, and beat the revenue estimate by 12.32% [2]. - For the current fiscal year, Arcutis is expected to post earnings of -$0.46 per share on revenues of $329.85 million, reflecting a 60.34% change in EPS and a 67.83% change in revenues. For the next fiscal year, the company is projected to earn $0.10 per share on revenues of $430.73 million, indicating a year-over-year change of 121.2% in EPS and 30.58% in revenues [3]. Valuation Metrics - Despite being at a 52-week high, the future valuation metrics are crucial for assessing potential stock performance. The Zacks Style Scores provide insights into various investment styles, with Arcutis having a Value Score of D, a Growth Score of A, and a Momentum Score of C, resulting in a VGM Score of B [4][6]. Zacks Rank - Arcutis Biotherapeutics holds a Zacks Rank of 2 (Buy), supported by a solid earnings estimate revision trend. This rank is considered more significant than the VGM Score, indicating a favorable outlook for the stock [7][8].
The Magnificent 7 Mirage: Why It Might Be Time To Rethink Your S&P 500 Index Fund
Benzinga· 2025-09-30 09:16
Your S&P 500 Index Fund Is Actually a Concentrated Tech Bet in Disguise.The Index That Isn’t What It SaysThe S&P 500 was created in 1957 to track the performance of America’s 500 largest companies, offering investors broad exposure to the U.S. economy. But somewhere along the way, it slowly transformed into something else entirely. Today, buying the S&P 500 means making a concentrated bet on just ten companies, with the top three (NVIDIA, Microsoft, and Apple) controlling more market weight than the smalles ...
PRDO vs. UTI: Which Stock Is the Better Value Option?
ZACKS· 2025-09-25 16:41
Investors interested in Schools stocks are likely familiar with Perdoceo Education (PRDO) and Universal Technical Institute (UTI) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on ...
Corning Incorporated (GLW) Hits Fresh High: Is There Still Room to Run?
ZACKS· 2025-09-24 14:15
Shares of Corning (GLW) have been strong performers lately, with the stock up 20.2% over the past month. The stock hit a new 52-week high of $81.02 in the previous session. Corning has gained 70.5% since the start of the year compared to the 22.6% gain for the Zacks Computer and Technology sector and the 63.1% return for the Zacks Communication - Components industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimat ...